505 8th Avenue S.W.
Suit 420
Calgary, AB T2P 1G2
Canada
403-770-2469
https://marvelbiotechnology.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. J. Roderick Matheson | Executive Chairman & CEO | 109,64k | N/A | N/A |
Dr. Mark Williams M.B.A., Ph.D. | President, Chief Science Officer & Director | 109,64k | N/A | 1972 |
Mr. Harpreet Nijjar C.M.A., CPA | Chief Financial Officer | 60,3k | N/A | 1988 |
Ms. Jacqueline Groot | Corporate Secretary | N/A | N/A | N/A |
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.
Marvel Biosciences Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.